CoChat
Sign Up
Cited by 76Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHealthcare Policy and Management

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program

Gordon, Adam J., Lo-Ciganic, Wei-Hsuan, Cochran, Gerald, Gellad, Walid F., Cathers, Terri, Kelley, David, Donohue, Julie M.·2015·Journal of Addiction Medicine
DOI 10.1097/adm.0000000000000164
Open this paper in CoChat — free account

Abstract

OBJECTIVES: Use of buprenorphine - an effective treatment for opioid use disorders (OUDs) - has increased rapidly in recent years and is often financed by Medicaid. We investigated predictors of buprenorphine treatment, patterns of care, and quality of care in a large state Medicaid program. METHODS: Data from Pennsylvania Medicaid from 2007 to 2012 provided information regarding diagnoses, demographic characteristics, enrollment, and use of inpatient and outpatient services, and prescription drugs. We identified adult enrollees using buprenorphine, and examined prevalence of OUD diagnosis and patterns of use (duration and dose) and quality of care (physician visits, receipt of behavioral health counseling, urine drug screens, and other prescription drug use). We use a mixed logistic regression model to examine enrollee characteristics associated with buprenorphine use. RESULTS: The share of enrollees with OUD filling prescriptions for buprenorphine increased from 2985 (9.8%) to 12,691 (25.2%) from 2007 to 2012. Between 26.2 and 32.0% of enrollees using buprenorphine had no diagnosis of OUD, depending on the year. Only 60.1% of enrollees with buprenorphine use received at least one urine drug screen, 41.0% had behavioral health counseling services, and 34.7 and 38.0% had other opioid and benzodiazepine claims, respectively, concomitant with buprenorphine use. Quality of care was lower among those with no OUD diagnosis recorded. The mean daily doses of buprenorphine decreased over time. We found wide variation in likelihood of buprenorphine use among those with OUD based upon age, sex, and race. CONCLUSIONS: Increases in buprenorphine treatment in a Medicaid population were observed across time; however, increases varied by age, sex, and rate, and the quality of care received seemed to be generally poor. The quality of the provision of buprenorphine treatment occurring in Medicaid populations should be further explored.

Overview

Integrity signals

Registry

Crossref · 10.1097/adm.0000000000000164

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 1

  1. Clark, 2013, Responses of state medicaid programs to buprenorphine diversion: Doing more harm than good J Am Med Assoc Intern M, ed, 173, 1571

Cited by

Sorted by citations

See all 76

Related

See all

Metadata

Authors
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M.
Affiliations
  • University of Arizona (US)
  • VA Pittsburgh Healthcare System (US)
  • University of Pittsburgh (US)
  • Pennsylvania Department of Human Services (US)
Corresponding author
Gordon, Adam J.
ORCID
Venue
Journal of Addiction Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015-11
Volume
9
Issue
6
Pages
470-477
ISSN
1932-0620 (ISSN-L)
DOI
10.1097/adm.0000000000000164
OpenAlex
W1891063291
Cited by
76
References
35
Citations by year
2026: 3 · 2025: 1 · 2024: 8 · 2023: 7 · 2022: 5 · 2021: 15 · 2020: 10 · 2019: 11 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 2
FWCI
5.72
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Addiction Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Pennsylvania Department of Human Services
  • Centers for Disease Control and Prevention (U01CE002496)
  • VA Pittsburgh Healthcare System
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
Keywords
buprenorphine, opioid use disorder, Medicaid, quality of care, patterns of care, urine drug testing, benzodiazepine use, prescription drug use, racial disparities, sex disparities, age disparities
MeSH terms
Adolescent, Adult, Analgesics, Opioid, Buprenorphine, Female, Humans, Male, Medicaid, Middle Aged, Opioid-Related Disorders, Quality of Health Care, United States, Logistic Models, Prescription Drugs, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review